Figure 5
From: In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin
Antitumour activity of doxorubicin in the presence or absence of TBN. Tumours consisted of parental (C) or transfected L5178 cells (A, B) growing subcutaneously in DBA/2 mice. When the tumour size reached 0.5 cm diameter, the animals were randomised and treated every second day. The TBN (A: 10 mg kg–1; B: 50 mg kg–1) was administered (or not) i.p. 3 h before doxorubicin (A: 4 mg kg–1; B: 2 mg kg–1, C: 4 mg kg–1) was injected i.p. Animals were weighed every second day and the experiments were terminated on 12th day. The values represent mean ± s.e. of five to eight animals per group. Significant differences on the individual days between means of the ‘doxorubicin’ arm and the ‘doxorubicin ± TBN’ arm (A, B) or ‘control’ arm and the ‘doxorubicin’ arm (C) are indicated by *P<0.01, **P<0.001 and ***P<0.0001. No indication implies no significant difference between the means.
